Derek Maetzold Sells 830 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 830 shares of the company’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $40.35, for a total transaction of $33,490.50. Following the completion of the sale, the insider directly owned 33,530 shares of the company’s stock, valued at $1,352,935.50. The trade was a 2.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Castle Biosciences Stock Down 0.3%

Shares of Castle Biosciences stock traded down $0.13 on Monday, hitting $39.27. 264,578 shares of the company traded hands, compared to its average volume of 451,151. The company has a quick ratio of 6.31, a current ratio of 6.47 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12-month low of $14.59 and a 12-month high of $42.17. The company has a 50-day moving average price of $34.59 and a 200 day moving average price of $25.50. The company has a market cap of $1.15 billion, a PE ratio of -87.27 and a beta of 1.14.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.32. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. The company had revenue of $80.55 million for the quarter, compared to analyst estimates of $71.06 million. Sell-side analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Hedge Funds Weigh In On Castle Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Schroder Investment Management Group grew its position in shares of Castle Biosciences by 8.6% during the 2nd quarter. Schroder Investment Management Group now owns 648,572 shares of the company’s stock worth $13,198,000 after purchasing an additional 51,483 shares in the last quarter. Advisors Capital Management LLC lifted its position in shares of Castle Biosciences by 21.9% during the 2nd quarter. Advisors Capital Management LLC now owns 245,867 shares of the company’s stock valued at $5,021,000 after acquiring an additional 44,180 shares during the period. Cubist Systematic Strategies LLC grew its holdings in shares of Castle Biosciences by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 237,698 shares of the company’s stock worth $4,759,000 after purchasing an additional 60,161 shares in the last quarter. Squarepoint Ops LLC increased its position in shares of Castle Biosciences by 29.1% in the second quarter. Squarepoint Ops LLC now owns 125,719 shares of the company’s stock worth $2,567,000 after purchasing an additional 28,359 shares during the period. Finally, Caxton Associates LLP acquired a new position in Castle Biosciences in the first quarter valued at about $329,000. 92.60% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. BTIG Research lifted their target price on shares of Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Robert W. Baird raised their price target on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 4th. Canaccord Genuity Group boosted their price target on shares of Castle Biosciences from $37.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Castle Biosciences in a research note on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Castle Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.